Leatt Corporation Announces Results for the Third Quarter 2026

Leatt Corp (LEAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Leatt Corporation Announces Results for the Third Quarter 2026 Global revenues increase 43% to $20.46 million, highest quarterly revenues in four years; Net income increases 309% to $2.20 million CAPE TOWN, South Africa , (November 12, 2026) – Leatt Corporation (OTCQ

Original reporting
Published Nov 12, 2026, 1:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LEAT
Bullish
high confidence
Mentioned
$LEAT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LEATBullishMed
01

Why it matters

Earnings beat and margin expansion provide a fresh catalyst for the stock, which could see buying interest.

02

Market read

The earnings release is the primary news driver; peers are mentioned only for comparison.

03

What to watch

Potential supply‑chain risks from trade tariffs and reliance on discretionary spending.

Relevance 7/10Novelty 7/10Timing: today, after the filing and before the conference call

Background

Leatt Corp (OTCQB: LEAT) filed a Form 8‑K reporting its third‑quarter 2026 financial results.

Company-level read

Ticker impact

$LEATBullishHigh confidence
Context

Leatt Corp disclosed Q3 2026 results with revenue up 43% to $20.46M and net income up 309% to $2.20M.

Expected impact

likely upward pressure as the market prices in the earnings beat and revenue growth.

Evidence & confidence

Revenue and profit surged year‑over‑year, margins improved, and new product launches were highlighted, providing a clear catalyst for buying.

Market effects

Positive signal for the protective‑equipment and outdoor‑sports gear sector, may lift peers.

Boosts sentiment for small‑cap US OTC listings.

Limited to niche consumer‑goods segment; no broad market effect.

Counterpoint

Growth may be unsustainable; inventory reductions could signal demand softening.

Key entities

  • Leatt Corp

    Developer and marketer of protective equipment for extreme sports.

Related articles

$LEATMed

Leatt Corp Announces Results for the Second Quarter 2026

Leatt Corp (LEAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Leatt Corp Announces Results for the Second Quarter 2026 Global revenues increase 14% for first six months; Net income increases 19% for first six months CAPE TOWN, South Africa , (August 14, 2026) - Leatt Corporation (OTCQB: LEAT), a leading developer and marketer of head-to-toe

$SGPMedAI 8/10

SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates • Acquired Advanced Vision Science, Inc. (AVS), securing scalable commercial intraocular lens (IOL) manufacturing capacity for its Phase 3 lead product candidate the Bimatopro

$ONDSHighAI 8/10

Ondas Posts Record Q3 2026 Revenue of $167.5 Million on Strong Bookings and Backlog Growth; Raises Full-Year Outlook

Ondas Inc. (ONDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ondas Posts Record Q3 2026 Revenue of $167.5 Million on Strong Bookings and Backlog Growth; Raises Full-Year Outlook Record Q3 revenue of $167.5 million, up 100% sequentially and more than 16-fold year over year; pro forma organic revenue grew 64% year-over-year Capt

$MOVEMed

Corvex Reports Third Quarter 2026 Results

Corvex, Inc. (MOVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corvex Reports Third Quarter 2026 Results ARLINGTON, Va., Nov. 12, 2026 /PRNewswire/ -- Corvex, Inc. (Nasdaq: MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today reported financial results for the thi

$AVLNMed

Avalyn Pharma 3Q 2026: EPS ($0.67) — 10-Q Summary

Avalyn Pharma reported a wider net loss of $29.66M in Q3 2026, up 25.7% YoY, driven by higher R&D and administrative expenses. Diluted EPS was ($0.67). The company provided updates on clinical trials for AP01, AP02, and AP03, with topline data expected in late 2027. R&D costs increased by $3.4M, primarily due to AP02 trial expenses.